<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00775905</url>
  </required_header>
  <id_info>
    <org_study_id>50365</org_study_id>
    <nct_id>NCT00775905</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Amlodipine Tablets Under Fasting Conditions</brief_title>
  <official_title>The Objective of This Study Was to Compare the Rate and Extent of Absorption of Ranbaxy Amlodipine 10 mg Tablet to That of Norvasc® 10 mg Tablet After a Single, One Tablet Dose in Fasted Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ranbaxy Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ranbaxy Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to compare the rate and extent of absorption of Ranbaxy
      amlodipine 10 mg tablet to that of Norvasc® 10 mg tablet after a single, one4ablet dose in
      fasted subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was conducted as an open label, balanced, randomised, two-treatment, two-period,
      two-sequence, single-dose, crossover , bioequivalence study on Amlodipine besylate
      formulations comparing Amlodipine 10mg tablets of Ranbaxy Laboratories with (Norvasc®, Pfizer
      Inc USA, in healthy, adult, human, subjects under fasting conditions
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>amlodipine 10 mg tablets of Ranbaxy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Norvasc® 10 mg tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine 10 mg tablet</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is the individual a healthy, normal adult man and woman who volunteers to participate?
             ls s/he at least 18 years of age? Is his/her BMI between 19 and 30, inclusive? Is she
             willing .to avoid pregnancy by abstaining from sexual intercourse with a non-sterile
             male partner, or by the use one of the following methods: diaphragm + spermicide or
             condom + spermicide (at least 14 days before dosing), intra- uterine contraceptive
             device or hormonal contraceptives (at least 4 weeks prior to dosing), or has she been
             surgically sterile or post-menopausal at least six months prior to entering into the
             stndy?

          -  Is s/he considered .reliable and capable of understanding his/her responsibility and
             role in the study.

          -  Has s/he provided written informed consent?

        A no answer to any of the above questions indicated that the individual was ineligible for
        enrollment

        Exclusion Criteria:

          -  Does the individual have a history of allergy or hypersensitivity to amlodipine? Does
             s/he have clinically significant laboratory abnormalities that would interfere with
             the conduct or interpretation of the study or jeopardize his/her safety?

               -  Does s/he have significant history or clinical evidence of auto-immune,
                  cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic,
                  neurological, ongoing infection, pancreatic, or renal diseases that would
                  interfere with the conduct or interpretation of the study or jeopardize his/her
                  safety'?

               -  Is she nursing?

               -  Does s/he have serious psychological illness?

               -  Does s/he have significant h/story (within the past year) or clinical evidence of
                  alcohol or drug abuse? •

               -  Does s/he have a positive urine drug screen or a positive HIV-1, or hepatitis B
                  or C screen, or a positive pregnancy test? Has s/he consumed grapefruit or
                  grapefruit juice during the 7rday period preceding study initiation?

               -  Is s/he unable to refrain from the use of alcohol or xanthine-containing foods or
                  beverages during periods beginning 48 hours prior to study drug administration
                  and ending when the last blood sample has been taken in each study period?

               -  Has s/he used any prescription drug, other than hormonal contraceptives, during
                  the 14-day period prior to study initiation, or any OTC drug during the 72-hour
                  period preceding study initiation?

               -  Is s/he unable to refrain from the use of all concomitant medications, other than
                  hormonal contraceptives, during the study?

               -  Has s/he donated or lost blood, or participated in a clinical study which
                  involved the withdrawal of a large volume of blood (480 mL or more), during the
                  six week period preceding study initiation?

        Has s/he donated plasma during the two week period preceding study initiation? Has s/he
        received an investigational drug during the 30 day period preceding study initiation? Is
        s/he a heavy smoker (usually smoking more than 10 cigarettes per day)?
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SFBC Ft. Myers, Inc.</name>
      <address>
        <city>Fort Myers,</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.ranbaxy.com.</url>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/Enforce.html</url>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
  </link>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2008</study_first_posted>
  <last_update_submitted>October 16, 2008</last_update_submitted>
  <last_update_submitted_qc>October 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Tausif Monif</name_title>
    <organization>Ranbaxy Research Laboratories</organization>
  </responsible_party>
  <keyword>Bioequivalence amlodipine tablets fasting</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

